Real-world evidence confirmed the role of vinflunine as a standard treatment in platinum-pretreated metastatic urothelial cancer
Analysis of seven European studies in real word practice reinforced the value of vinflunine as standard single agent chemotherapy of metastatic urothelial cancer in patients after platinum-based chemotherapy. This study presented in the Genitourinary Cancers Symposium in San Francisco in February 2018 included only non-interventional studies published between 2014 and 2017.
The total number of patients in these studies was 750. Median OS (overall survival) ranged from 6.3 to 11.9 months being globally superior to the median OS in the phase III study. Median values of PFS (progression free survival) ranged from 2.8 to 6.2 months, ORR (overall response rate) from 13% to 29%. The OS was depended on the number of risk factors and starting dose of vinflunine. The favourable safety profile of vinflunine observed in the randomized studies was also confirmed. Main grade 3/4 toxicity was haematological, constipation seemed to be less frequent than previously reported.
As a multivariate analysis of the pivotal phase III study has shown, vinflunine may be of the greatest benefit in the subgroup of patients with baseline ECOG PS 0–1, hemoglobin > 10 g/dl and normal liver fiction (no liver metastases).
Source: Passalacqua R, Medioni J, Castellano D et al. Real world evidence of vinflunine in metastatic urothelial cancer: a systematic review of seven European studies. Presented at 2018 Genitourinary Cancer Symposium, San Francisco, February 2018.